PL332564A1 - Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases - Google Patents

Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases

Info

Publication number
PL332564A1
PL332564A1 PL99332564A PL33256499A PL332564A1 PL 332564 A1 PL332564 A1 PL 332564A1 PL 99332564 A PL99332564 A PL 99332564A PL 33256499 A PL33256499 A PL 33256499A PL 332564 A1 PL332564 A1 PL 332564A1
Authority
PL
Poland
Prior art keywords
spla
tricyclic compounds
soothing
drug
production
Prior art date
Application number
PL99332564A
Other languages
English (en)
Inventor
Nicholas James Bach
Jolie Anne Bastian
Douglas Wade Beight
Michael Dean Kinnick
Michael John Martinelli
Edward Dawid Mihelich
John Michael Morin
Daniel Jon Sall
Jason Scott Sawyer
Edward C R Smith
Tulio Suarez
Qiuping Wang
Thomas Michael Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL332564A1 publication Critical patent/PL332564A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL99332564A 1998-04-17 1999-04-16 Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases PL332564A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
PL332564A1 true PL332564A1 (en) 1999-10-25

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99332564A PL332564A1 (en) 1998-04-17 1999-04-16 Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases

Country Status (27)

Country Link
EP (2) EP0950661B1 (https=)
JP (1) JP4435325B2 (https=)
KR (1) KR19990083234A (https=)
CN (1) CN1235968A (https=)
AR (1) AR018185A1 (https=)
AT (2) ATE254128T1 (https=)
AU (1) AU757454B2 (https=)
BR (1) BR9901275A (https=)
CA (1) CA2269256A1 (https=)
CO (1) CO5080728A1 (https=)
CZ (1) CZ137199A3 (https=)
DE (2) DE69912670T2 (https=)
EA (1) EA003129B1 (https=)
ES (2) ES2213668T3 (https=)
HU (1) HUP9901219A1 (https=)
ID (1) ID23219A (https=)
IL (1) IL129484A0 (https=)
NO (1) NO991823L (https=)
NZ (1) NZ335252A (https=)
PE (1) PE20000472A1 (https=)
PL (1) PL332564A1 (https=)
SG (1) SG106035A1 (https=)
SV (1) SV1999000052A (https=)
TR (1) TR199900842A2 (https=)
TW (1) TW555760B (https=)
YU (1) YU19099A (https=)
ZA (1) ZA992773B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
WO2001074817A1 (en) * 2000-03-30 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Hydrazide derivatives
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
WO2002050029A2 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Tetracyclic derivatives as spla2 inhibitors
CA2441077A1 (en) 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
US7109231B2 (en) 2001-08-09 2006-09-19 Eli Lilly And Company Cyclohept[b]indole derivatives
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
WO2006050007A2 (en) 2004-11-01 2006-05-11 Wyeth Substituted indolizines and derivatives as cns agents
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
DK2697223T3 (en) * 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
SI2825541T1 (sl) 2012-03-16 2016-10-28 Vitae Pharmaceuticals, Inc. Modulatorji jetrnega receptorja X
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
BR9508298A (pt) * 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
EP0779271B1 (en) * 1995-12-13 2001-08-01 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
CA2269203A1 (en) * 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Also Published As

Publication number Publication date
EP1156050A2 (en) 2001-11-21
BR9901275A (pt) 2000-05-02
AR018185A1 (es) 2001-10-31
SG106035A1 (en) 2004-09-30
DE69914951T2 (de) 2004-12-23
TR199900842A2 (xx) 2000-09-21
ZA992773B (en) 2002-07-16
EP1156050A3 (en) 2001-11-28
SV1999000052A (es) 2000-03-14
KR19990083234A (ko) 1999-11-25
ATE259818T1 (de) 2004-03-15
AU2381899A (en) 1999-10-28
NZ335252A (en) 2000-11-24
CO5080728A1 (es) 2001-09-25
ID23219A (id) 2000-03-30
CZ137199A3 (cs) 1999-11-17
YU19099A (sh) 2001-09-28
DE69914951D1 (de) 2004-03-25
DE69912670D1 (de) 2003-12-18
ES2210979T3 (es) 2004-07-01
CN1235968A (zh) 1999-11-24
EA199900304A3 (ru) 2000-04-24
EA199900304A2 (ru) 1999-10-28
EP1156050B1 (en) 2004-02-18
TW555760B (en) 2003-10-01
PE20000472A1 (es) 2000-06-02
ATE254128T1 (de) 2003-11-15
IL129484A0 (en) 2000-02-29
ES2213668T3 (es) 2004-09-01
NO991823L (no) 1999-10-18
AU757454B2 (en) 2003-02-20
HU9901219D0 (en) 1999-06-28
DE69912670T2 (de) 2004-08-12
JPH11322745A (ja) 1999-11-24
CA2269256A1 (en) 1999-10-17
HUP9901219A1 (hu) 2000-08-28
JP4435325B2 (ja) 2010-03-17
EA003129B1 (ru) 2003-02-27
NO991823D0 (no) 1999-04-16
EP0950661B1 (en) 2003-11-12
EP0950661A1 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
PL332565A1 (en) Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases
PL332564A1 (en) Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases
IL161110A0 (en) Prevention and treatment of restenosis by local admistration of drug
EP1100508B8 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
HUP9600834A1 (en) Quinazoline derivatives, producing and using them for the treatment of hyperproliferative diseases in a mammal, and a pharmaceutical composition containing the compounds
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
PL339489A1 (en) Pre-filled ampoules and their production
HUP0104909A3 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity, process for their preparation and medicaments containing them
IL156550A0 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL113873A0 (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
HU9904392D0 (en) New derivatives of erythromycin, process for their production and their use as medicament
HUP0104116A3 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
PL311257A1 (en) New compounds and method of their production as well as pharmaceutical compounds and method of its production
DE69803190D1 (de) Einteiliges schwungrad mit aüsserem, verzahntem ring und dessen herstellungsverfahren
PL308074A1 (en) Derivatives of borone peptides, their production as well as their application in medical therapy
PL312693A1 (en) Oxathiolanes, method of their production and pharmaceutical compounds containing them
MXPA02009434A (es) Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.
IL141501A0 (en) Alginate capsules for use in the treatment of brain tumour
AU6126498A (en) Method for the treatment of drug addiction and homeopathic remedy
HUP0203443A3 (en) Novel contraceptive medicament and method for producing the same
AU6274101A (en) Medicines for the prevention and treatment of neurodegenerative diseases
PL326844A1 (en) Novel derivatives of quinosalinodione, their production and implementation in drugs
PL337234A1 (en) Derivatives of 5-naphtalen-1-yl-1,3-dioxane, their production and therapeutic application

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)